The results challenge the claims made by Cogmed to the effect that the program is effective in treating attention problems and improving performance in daily life over the long term in adults with ADHD.
Summary
The primary objective of this study was to examine the effects of the Cogmed training program on working memory among youths 7 to 13 years old, with attention deficit/hyperactivity disorder (ADHD) type and comorbidity controlled for. A secondary objective was to examine the generalization of effects to ADHD symptoms, nonverbal reasoning, attentional and executive functions, inhibition, reading comprehension, and mathematical reasoning. Participants were under pharmacological treatment for ADHD combined type and a comorbidity. They were randomized into an experimental group that received the Cogmed program and an active control group that received a low‐intensity comparison version of the training. They were evaluated at three time points: 6 weeks prior to intervention onset (T1), immediately prior to onset (T2), and 1 week following intervention completion (T3). Results indicate no significant effect attributable to the Cogmed program. The fact that participants were on medication at the time of training and evaluation normalized their performances and limited the detection of effects. Moreover, cognitive training did not lead to a reduction in ADHD symptoms or to an improvement in the other cognitive functions measured or in academic performance. The results of this study do not demonstrate the effectiveness of the Cogmed program for youths with ADHD combined type and a comorbidity when they receive the training while under pharmacological treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.